 Parsippany, NJ, April 05, 2021 GLOBE NEWSWIRE -- Interpace Biosciences, Inc. Interpace or the Company OTCQX: IDXG announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis PLA code that specifically identifies ThyGeNEXT as a distinct test from any other test or service. PLA codes are an addition to the current procedural terminology CPT code set approved by the American Medical Association CPT Editorial Panel. PLA codes are alpha-numeric CPT codes with a corresponding descriptor for labs that want to more specifically identify their test. The new PLA code for ThyGeNEXT is 0245U and the reimbursement for this code remains 2,919, representing a significant price increase over the prior reimbursement level of 560. In December, 2020, Novitas issued a new local coverage determination LCD for ThyGeNEXT that reflects the tests enhanced mutation panel. In 2020, Interpace processed approximately 15,000 ThyGeNEXT tests for over 700 physicians. 